We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Tbu2.0
Tributyrin Research
Mostly mechanism / observational
11 peer-reviewed studies
What the evidence says
Mostly mechanism / observational
Most Tributyrin studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from mixed-quality randomised trials published 1998–2026 with a typical study size of 17 participants.
Based on 11 studies · 1 RCT · 62 total participants
Confidence
Low confidence
By outcome
Butyrate delivery & target engagement
Too few graded studies7 studies
Cancer & antiproliferative effects
Too few graded studies4 studies
Neurological & psychiatric conditions
Too few graded studies2 studies
Inflammation
Too few graded studies1 study
Gut barrier & intestinal integrity
Too few graded studies1 study
Safety & dose-limiting effects
Too few graded studies1 study
By the numbers
Pulled from 10 studies with measurable effects
People studied
62
typical study: 17 people
Strongest designs
1
0 pooled, 1 randomised
How long studies ran
1–4 weeks
1
Populations Studied
Men with overweight/obesity1
Mice and rats1
People with Parkinson's disease plus normal controls1
Human visceral adipose tissue ex vivo1
Active research area
5 studies in the last 5 years
199820122026
1Review2026
In plain English: This framework provides a testable model and supports interventional studies to determine whether restoration of SCFA signaling-such as through early administration of butyrate-producing microbes or tributyrin (a stable butyrate triglyceride)-can favorably alter immune trajectories and improve clinical outcomes.
Yip YY, Ho KM. · Journal of critical care (2026)
These pathways provide a mechanistic bridge between these seemingly opposing states.
They are not merely consequences of sepsis but active determinants of immune trajectory.
Loss of SCFA- producing microbiota may impair immune regulation and promote dysregulated cell death, sustaining both hyperinflammatory and immunosuppressive states.
2Postprandial plasma butyrate and hexanoateCrossoverCited 18×n=12 · very small study2022
In plain English: In TIM-1, tributyrin/caproin was rapidly cleaved in the gastric compartment whereas the release of SCFA from Akovita SCT occurred predominantly in the small intestine.
van Deuren T et al. · Front Nutr (2022)
In a laboratory model of the stomach and small intestine (TIM-1), a tributyrin and tricaproin mix was rapidly broken down in the stomach compartment. A modified triglyceride, Akovita SCT, released its short-chain fatty acids mainly in the small intestine.
The human part tested Akovita SCT, not tributyrin. 14 men with overweight or obesity were randomised in a double-blind crossover to three doses or placebo, and 12 finished all test days.
The medium dose increased postprandial butyrate (P < 0.05) and the high dose showed only a trend (P < 0.10). Both raised hexanoate (P < 0.05).
In plain English: These studies document the ability to use oral administration of tributyrin to achieve pharmacologically relevant concentrations of butyrate in rodent plasma.
Egorin MJ et al. · Cancer Chemother Pharmacol (1999)
A pharmacokinetic study in mice and rats, not people.
In mice, oral tributyrin at 10.3 g/kg gave peak plasma butyrate of about 1.75 mM, staying above 1 mM for between 10 and 60 minutes, but about 10% of mice at that dose died acutely. At 7.8 g/kg butyrate reached about 1 mM and no mouse died.
Oral sodium butyrate at 5 g/kg gave a peak of about 9 mM, above 1 mM for 90 minutes.
4Target engagement by [11C]butyrate PETOpen-LabelCited 1×n=17 · very small study2026
In plain English: Given these findings, tributyrin warrants further investigation via larger, placebo-controlled trials as a potential complementary therapy for Parkinson's disease.
Bohnen JLB et al. · Neurotherapeutics (2026)
An open-label study with no placebo group and no blinding. Fourteen people with Parkinson's disease and three healthy controls took 500 mg tributyrin by mouth three times daily for about 30 days. The healthy controls also took tributyrin, they were not a comparison arm.
The authors report a reassuring safety profile with high rates of adherence.
Ten participants had [11C]butyrate PET scans before and after, which showed organ-specific changes in butyrate uptake in brain, liver, heart and gut. This shows the compound reaches tissue, not that it helps.
In plain English: These studies suggest that the short-chain fatty acid, sodium butyrate, and its triacylglyceride form, tributyrin, might alleviate the chronic inflammation that is associated with many individuals with obesity.
Rafiei H et al. · Int J Obes (Lond) (2024)
A laboratory study on pieces of human visceral fat incubated in culture plates with LPS, not a study in people.
Sodium butyrate and tributyrin both significantly reduced LPS-induced inflammatory cytokine and chemokine production in all adipose samples tested.
The abstract does not compare tributyrin with sodium butyrate directly, so it does not show that either is better.
6Plasma butyrate pharmacokinetics and tumour responseOpen-LabelCited 75×n=20 · very small study2003
In plain English: No objective responses were seen.
Edelman MJ et al. · Cancer Chemother Pharmacol (2003)
20 patients with advanced solid tumours and no other treatment options took tributyrin 150 to 200 mg/kg three times daily, with no control group.
There was no dose-limiting toxicity. Escalation was halted at the 200 mg/kg three times daily level due to the number of capsules required.
A median butyrate concentration of 52 microM was obtained but there was considerable interpatient variability. The authors cite in vitro activity at levels above 50-100 microM.
7Plasma butyrate pharmacokinetics and toxicityOpen-LabelCited 133×n=13 · very small study1998
In plain English: Peak plasma butyrate concentrations occurred between 0.25 and 3 h after dose, increased with dose, and ranged from 0 to 0.45 mM.
Conley BA et al. · Clin Cancer Res (1998)
13 patients with solid tumours took tributyrin at escalating doses of 50 to 400 mg/kg/day, once daily for 3 weeks then 1 week off, with no control group.
Peak plasma butyrate occurred 0.25 to 3 hours after a dose, increased with dose, and ranged from 0 to 0.45 mM. Peaks did not increase in the three patients who had their own dose escalated.
Butyrate had disappeared from plasma by 5 hours after a dose.
8Intestinal tight-junction protein expressionAnimalCited 90×2014
In plain English: Protection of the intestine with tributyrin supplementation was accompanied by mitigation of EtOH-induced increases in aspartate aminotransferase and inflammatory measures in the short-term and acute EtOH exposure protocols, but not after chronic EtOH feeding.
Cresci GA et al. · Alcohol Clin Exp Res (2014)
A mouse study of alcohol-induced gut injury, using chronic (25 days), short-term (2 days) or single-dose alcohol.
All three alcohol protocols reduced tight-junction proteins (ZO-1, occludin) and a butyrate receptor and transporter in the gut, and tributyrin protected against these effects.
Tributyrin also reduced the rise in liver enzyme and inflammatory measures after short-term and acute alcohol, but not after chronic alcohol feeding.
9Cell growth inhibition and differentiationIn VitroCited 56×2001
In plain English: Tributyrin was more potent in inhibiting growth and inducing cell differentiation than natural butyrate.
Gaschott T et al. · J Nutr (2001)
A laboratory study in Caco-2 cells, a human colon cancer cell line, not a study in people.
Tributyrin was more potent in inhibiting growth and inducing cell differentiation than natural butyrate.
The effect was further enhanced by physiological concentrations of active vitamin D (dihydroxycholecalciferol), which the authors attribute to tributyrin increasing vitamin D receptor expression. Receptor binding rose 1.5-fold with no change in affinity.
11Feasibility and acceptability (protocol; no results)PilotCited 2×2025
In plain English: The primary aim of this pilot study is to assess the feasibility and acceptability of an 8-week oral supplementation with tributyrin, a triglyceride form of butyrate (4 g/day), added to usual treatment with antidepressant medication in 24 patients with mild-to-severe MDD aged 18-65 years.
Korenblik V et al. · BMJ Open (2025)
A study protocol. It describes a planned trial and reports no results.
Planned as a double-blind, 1:1 randomised, placebo-controlled pilot in 24 adults with major depressive disorder, adding tributyrin 4 g/day to antidepressant medication for 8 weeks.
The primary aim is feasibility and acceptability, not efficacy. Depressive symptoms, anhedonia and affect are secondary outcomes.